Studies have shown that CBD may be particularly beneficial for two rare forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. The syndromes typically appear in childhood, resist treatment, and cause severe symptoms, including seizures.
Studies in the U.S. of Epidiolex (a plant-based CBD formulation) have been ongoing for a number of years. Data from these studies has helped provide evidence that led to the FDA approval of this product on June 25, 2018. Epidiolex is a purified (> 98% oil-based) CBD extract from the cannabis plant.